PreMD Provides Update on 510(k) Application for PR...( TORONTO Sept. 6 / Predictive medi...),Health

TORONTO, Sept. 6 /PRNewswire-FirstCall/ - Predictive medicine company PreMD Inc. (TSX: PMD; Amex: PME) today announced that it has received questions from the U.S. Food and Drug Administration (FDA) regarding its 510(k) application for an expanded regulatory claim for its POC skin cholesterol test. PreMD submitted the 510(k) application to the FDA in June 2007. The submission seeks to obtain broader clearance in the assessment of cardiovascular disease risk in individuals without known disease. PreMD believes the specific matters raised by the FDA are fully addressable and the Company plans to submit a response within the alloted timeline of 30 days.

"Receiving questions from the FDA is a common part of the regulatory process," said Brent Norton, president and chief executive officer of PreMD. "Based on our current information and analysis, we plan to provide the FDA with the information they requested within 30 days. We are confident that we are on the path towards expanded regulatory clearance."

About PreMD Inc.

PreMD Inc. is a leader in predictive medicine, dedicated to developing rapid, non-invasive tests for the early detection of life-threatening diseases. PreMD's cardiovascular products are branded as PREVU(x) Skin Cholesterol Test, to be marketed and distributed by AstraZeneca. The company's cancer tests include ColorectAlert(TM), LungAlert(TM) and a breast cancer test. PreMD's head office is located in Toronto, Ontario and its research and product development facility is at McMaster University in Hamilton, Ontario. For more information about PREVU(x), please visit http://www.prevu.com.

This press release contains forward-looking statements. These statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the succ
'/>"/>